Zhan et al. [12] found increased glutamine metabolism and upregulation of glutaminase in both JAK2V617F mutant cells and clonally derived erythroid progenitor cells from JAK2V617F-positive MPN patients, as well as increased glutaminase levels with disease progression. This evidence concerns the gene GLS and myeloproliferative neoplasm.